Associated Papers
The association of CYP2C19 LoF alleles with adverse clinical outcomes in stroke patients taking clopidogrel: An updated meta-analysis.
Biswas M et al.
Clinical and Translational Science, 2024
A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy.
Angulo-Aguado M et al.
Journal of Personalized Medicine, 2021
PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study.
Tanaka K et al.
Plos One, 2021
The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
Zhang Z et al.
Bmc Pharmacology & Toxicology, 2020
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Tresukosol D et al.
Plos One, 2014
Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Zhang L et al.
Thrombosis Research, 2013
Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response.
Kreutz RP et al.
Clinical Pharmacology : Advances and Applications, 2013
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review).
Martino A et al.
International Journal of Oncology, 2012
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
Ma TK et al.
British Journal of Clinical Pharmacology, 2011
Clinically relevant genetic variations in drug metabolizing enzymes.
Pinto N et al.
Current Drug Metabolism, 2011
Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response.
Simoni M et al.
Human Reproduction Update, 0
Select a paper to view details